Plecanatide improves symptoms of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) across age subgroups: an analysis of four phase 3 trials

Staller K, et al.

Plecanatide provided clinically meaningful improvements in health-related quality of life in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: a post-hoc analysis

Brenner DM, et al.

Plecanatide improved stool consistency in patients with chronic idiopathic constipation regardless of baseline BSFS: a post-hoc analysis

Harris LA, et al.

Plecanatide improves abdominal symptoms in individuals with chronic idiopathic constipation and irritable bowel syndrome with constipation, including those experiencing severe bloating, pain, and discomfort

Sayuk GS, et al.

Plecanatide produces a more rapid and durable clinical response compared to placebo in patients with chronic idiopathic constipation: a post-hoc analysis of two randomized controlled trials

Shah E, et al.

Treatment satisfaction and improvement in quality of life with plecanatide among patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: analyses from four phase 3 trials

Brenner DM, et al.

Plecanatide is effective in severely constipated patients with chronic idiopathic constipation and irritable bowel syndrome with constipation

Cash B , et al.

Plecanatide provides meaningful improvements in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation reporting reduced quality of life: analyses from four randomized phase 3 trials [Encore]

Brenner DM, et al.

Early response to plecanatide predicts overall treatment response in patients with chronic idiopathic constipation

Martinez de Andino N, et al.

Plecanatide provides meaningful improvements in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation reporting reduced quality of life: analyses from four randomized phase 3 trials

Brenner DM, et al.

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys [Encore]

Quigley EMM, et al.

The impact of plecanatide on abdominal pain in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: analysis from four phase 3 studies

Barucha A, et al.

Efficacy of plecanatide in bloated patients with chronic idiopathic constipation and moderately to severely bloated patients with irritable bowel syndrome with constipation

Brenner DM, et al.

Efficacy and safety of plecanatide in patients with chronic idiopathic constipation or irritable bowel syndrome with constipation: intrinsic factors analyses from four studies

Chang C, et al.

Efficacy and safety of plecanatide in patients with chronic idiopathic constipation: pooled analysis of two phase 3 trials stratified by concomitant acid suppression use

Moshiree B, et al.

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys [Encore]

Weaver J, et al.

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome-constipation: analysis of abdominal pain from four randomized phase 3 clinical trials

Bharucha AE, et al.

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome–constipation: analysis of symptoms' responses by baseline bloating severity from four randomized phase 3 clinical trials

Brenner DM, et al.

Safety and efficacy evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome-constipation in patients aged 65 years or older

Menees S, et al.

Pharmacist consultation in individuals with chronic idiopathic constipation or irritable bowel syndrome with constipation: results from the BURDEN-CIC and BURDEN IBS-C surveys

Weaver J, et al.

Plecanatide for treating chronic idiopathic constipation: a pooled analysis of efficacy and safety [Encore ]

Franklin H, et al.

Impact of plecanatide on symptoms and quality of life for patients with chronic idiopathic constipation: analysis of PAC-SYM and PAC-QOL from two phase III clinical trials

Brenner D, et al.

Plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome-constipation: analysis of abdominal bloating from four randomized phase 3 clinical trials

Franklin H, et al.

Efficacy of plecanatide for patients with chronic idiopathic constipation and irritable bowel syndrome–constipation with abdominal bloating: analysis from four randomized phase 3 clinical trials 

Brenner D, et al.

Plecanatide for treating chronic idiopathic constipation: a pooled analysis of efficacy and safety  [Encore]

Franklin H, et al.

Communication between clinicians and patients with chronic idiopathic constipation or irritable bowel syndrome with constipation: an ethnographic study of office visits

Sayuk GS, et al.

Evaluation of the safety and tolerability of plecanatide in CIC and IBS-C patients aged 65 and older

Menees SB, et al.

Acid suppression therapy does not affect the efficacy of plecanatide: a patient-level pooled analysis of two large randomized controlled trials

Moshiree B, et al.

Evaluation of therapeutic risk/benefit ratios from pooled plecanatide and linaclotide phase 3 trials in adult patients with chronic idiopathic constipation

Brenner DM, et al.

Outcome radar plots of aggregated data from two phase III placebo-controlled trials of plecanatide in chronic idiopathic constipation

Sayuk GS, et al.

Plecanatide significantly improved health-related quality of life in two randomized clinical trials of patients with chronic idiopathic constipation

Hixson M, et al.

Plecanatide for treating chronic idiopathic constipation: a pooled analysis of efficacy and safety

Hixson M, et al.

Impact of plecanatide on quality of life for patients with chronic idiopathic constipation: analysis of PAC-SYM and PAC-QOL from two randomized phase 3 clinical trials

Hixson M, et al.

BURDEN–CIC (Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation) study: a severity analysis

Horn J, et al.

Understanding the cost of chronic idiopathic constipation: evidence from the BURDEN–CIC (Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation) study

Harris LA, et al.

Results from the BURDEN-CIC study (Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation)

Harris LA, et al.

The uroguanylin analog plecanatide activates guanylate cyclase-C predominantly in the lumen of the proximal small intestine to stimulate chloride and fluid secretion and increase GI transit in animal models

Joshi A, et al.

Plecanatide for the treatment of chronic idiopathic constipation: an analysis of patient-reported symptoms associated with constipation

Miner PB, et al.

Efficacy and safety of plecanatide in patients with chronic idiopathic constipation: an analysis of patients with moderate to very severe bloating

Rao SSC, et al.

Plecanatide and dolcanatide, guanylate cyclase-C agonists, attenuate paracellular permeability and enhance normal localization of tight junctional proteins to maintain intestinal barrier function

Thadi A, et al.

The impact of plecanatide on quality of life for patients with chronic idiopathic constipation: results from two phase 3 clinical studies

Hixson M, et al.

Understanding the cost of chronic idiopathic constipation: evidence from the BURDEN–CIC (Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation) study

Quigley E, et al.

Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study

De La Portilla M, et al.

Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation: pooled results from two phase 3 studies

Rao S, et al.

Structural and dynamic features of plecanatide: insights from molecular dynamics simulations

Brancale A, et al.

Effect of plecanatide on stool consistency in the treatment of chronic idiopathic constipation: results from two phase III studies

Krause R, et al.

A phase III study of the efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (study-00)

Miner PB, et al.

Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation: results from a multicenter phase III study (study-03)

Miner PB, et al.

Effect of plecanatide on patient assessments in chronic idiopathic constipation: results from two phase III studies

Nualart M, et al.

Plecanatide, like uroguanylin, activates guanylate cyclase-C signaling in a pH-dependent manner in T84 cells, and in murine intestinal epithelial cells and tissues

Patwa V, et al.

Plecanatide produces a diarrhea plateau effect in chronic idiopathic constipation patients

Fogel R, et al.

Acceleration of time to first bowel movement in chronic idiopathic constipation patients receiving plecanatide in a large, multicenter, dose-ranging study

Miner PB, et al.

Plecanatide, a novel guanylate cyclase-C receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation: results from a 951 patient, 12 week, multi-center trial

Miner P, et al.

Orally administered plecanatide, a guanylate cyclase-C agonist, acts in the proximal intestine to stimulate fluid secretion to normalize bowel movement

Comiskey S, et al.

Orally administered plecanatide, a guanylate cyclase-C agonist, acts in the lumen of the proximal intestine to facilitate normal bowel movement in mice and monkeys

Comiskey S, et al.

Plecanatide, a superior analog of uroguanylin, as an oral drug candidate for treatment of gastrointestinal functional disorders and diseases

Shailubhai K, et al.

Plecanatide, a guanylate cyclase C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study

Shailubhai K, et al.

A comparison of the physical and pharmacological properties of plecanatide (SP-304) and the human hormone uroguanylin

Solinga R, et al.

Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation

Shailubhai K, et al.